Madrigal Pharmaceuticals, Inc. (MDGL) 2017年年度报告「NASDAQ」.pdf

1、Use these links to rapidly review the document Table of Contents INDEX TO CONSOLIDATED FINANCIAL STATEMENTSTable of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KCommission file number:001-33277MADRIGAL PHARMACEUTICALS,INC.(Exact name of registrant as specified

2、in its charter)Delaware(State or other jurisdiction ofincorporation or organization)04-3508648(I.R.S.EmployerIdentification No.)Four Tower Bridge200 Barr Harbor Drive,Suite 400West Conshohocken,Pennsylvania(Address of principal executive offices)19428(Zip Code)Registrants telephone number,including

3、area code:(484)380-9263 Securities registered pursuant to Section 12(b)of the Exchange Act:Title of each class Name of each exchange on whichregisteredCommon Stock,$0.0001 Par Value PerShare The NASDAQ Stock Market LLC Securities registered pursuant to Section 12(g)of the Exchange Act:None.Indicate

4、by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Exchange Act.Yes o No Indicate by check mark whether the regist

5、rant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorterperiod that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes N

6、o o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to Rule 405of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter